Comunicati.net - Comunicati pubblicati - Varie Comunicati.net - Comunicati pubblicati - Varie Fri, 24 Feb 2017 18:05:48 +0100 Zend_Feed_Writer 1.11.10 (http://framework.zend.com) http://comunicati.net/comunicati/turismo/varie/1 PRN: China's Largest Gifts & Home Show Will Be Launched In April 2017 Fri, 24 Feb 2017 03:09:12 +0100 http://comunicati.net/comunicati/turismo/varie/422743.html http://comunicati.net/comunicati/turismo/varie/422743.html PR Newswire Turismo PR Newswire Turismo

China's Largest Gifts & Home Show Will Be Launched In April 2017

  [23-February-2017]  

SHENZHEN, China, Feb. 24, 2017 /PRNewswire/ -- The 25th China (Shenzhen) International Gifts, Handicrafts, Watches & Houseware Fair is planned to be held from 25-28, April, 2017 at the Shenzhen Convention & Exhibition Center. China's leading gift trade show with 5,000 booths on site, you can source around 500,000 kinds of creative and high-quality products directly from top suppliers at competitive prices. The event is organized by Reed Huabo Exhibitions.

The largest gift sourcing event in mainland China

The domestic gifts community and industry professionals come together at this unique sourcing platform to touch, experience, feel, compare and purchase directly from all ranges of gift products, from business, corporate, promotional, original design, personal or seasonal gifts. It is estimated that more than 20 exhibit categories will be on display throughout 110,000sqm of exhibition area in 9 halls.

Meet face-to-face to build real relationships with 2,500 exhibitors boasting manufacturing capability and showcasing new trends, innovations, and a wide range of products specific to your business and gather competitive intelligence to lead your business towards success.

Show highlights

  • Maker Gallery Pavilion to help buyers spot unique, creative products. Various innovative intelligent products with great design and high performance will be displayed at the show.
  • 40% of local manufacturers have strong production strength in OEM and ODM, and products customization.
  • Over 20 gifts and business associations from mainland China will present their local specialty products at the venue.
  • 5 categories of up-to-date electronic products -- Consumer Electronics, Mobile Electronics, Household Appliances, 3C Digital and Smart Living -- will be presented at the show.

Value-added services will be provided to maximize the efficiency of your participation in the trade event and meet all your needs under a single roof

Buyers will enjoy a comprehensive suite of services which will bring more trade opportunities and industry resources.

  • Free translation service on-site for 1 hour for pre-registered overseas buyers.
  • Professional match-making services help buyers find suitable products and suppliers.

About Reed Huabo

Reed Huabo, the most influential exhibition company in China, is a member company of Reed Exhibitions - the world's leading event organizer, based in the UK. It is committed to leading the industry's development and continuously creating value for customers from all over the world.

For more info and to get free tickets, please visit us at: www.chinagiftsfair.com

Media Contact:

Tracy Liu
+85-755-3398-9311
tracy.liu@reedhuabo.com 


]]>
PRN: Melbourne-based Software Engineering Firm, Ocean Software, Secures Their 13th International Military Customer for the Supply of Their COTS Product, FlightPro(R) Thu, 23 Feb 2017 23:00:22 +0100 http://comunicati.net/comunicati/turismo/varie/422738.html http://comunicati.net/comunicati/turismo/varie/422738.html PR Newswire Turismo PR Newswire Turismo

Melbourne-based Software Engineering Firm, Ocean Software, Secures Their 13th International Military Customer for the Supply of Their COTS Product, FlightPro(R)

  [23-February-2017]  

MELBOURNE, Australia, Feb. 23, 2017 /PRNewswire/ -- The latest Military organisation to procure FlightPro® is the Belgian Air Component, who will be using the software to manage all aspects of their military flying operations, including training. FlightPro's® selection, after a rigorous competitive tender process, is evidence of the critical nature of the capability sought by the Belgian MoD.

The deal with the Belgian Air Component secures Ocean Software's dominant global position in the Enterprise Aviation Operations Management Software space, particularly across Europe, as Belgium joins Ocean's rapidly expanding European customer list which includes the European Defence Agency, the Royal Air Force, the Finnish Air Force, Lufthansa, BAE Systems, and ST Aero.

Ocean Software originally developed FlightPro® in 1993 for the Royal Australian Air Force, where it is still relied upon to ensure the day-to-day operations of flying squadrons are handled efficiently and safely.

FlightPro® was designed to simplify the multi-dimensional, challenging task of getting correctly qualified pilots into the right aircraft at the right time for both training and military operations purposes. Historically this has required highly skilled and experienced operations personnel, usually flying instructors, to manage multiple manual processes and legacy systems in order to achieve the end goal. FlightPro® simplifies and automates many of the tasks associated with this, and brings all the necessary data together within a single system, to handle everything from scheduling, training, qualification and currency management, to maintenance and reporting, as well as everything in between.

Ocean Software's General Manager, Bruce Moors says, "The hard work of the Belgian Air Component and Ocean Software's team to make this happen has assured recognition of the principles behind everything we do; that is to build and deliver high quality systems. FlightPro® is a proven and highly regarded product that has been developed and enhanced over more than 20 years by people who understand the extreme complexities of Aviation Operations, particularly within Military environments."

The Belgian Air Component seeks to have the FlightPro® Software up and running by the end of this year. The Belgian Project Officer, Steven Van der Vorst, says, "Future challenges such as 'do more with less' and increasingly complex weapon systems including the A400M, NH90 and future fighters will require ever more efficient tools such as FlightPro® in order for the weapon systems to be employed effectively."

About Ocean Software

Ocean Software designs, develops, and delivers Enterprise Software solutions for military, government, and corporate customers around the world.

Ocean's solutions are widely regarded as the gold standard in their respective classes due to their completeness, levels of support, ongoing development, training and documentation. Our products form the core systems behind highly complex operating environments including: Command and Control, Operations & Training Management Healthcare, Supply Chain Management, and eCommerce. For more information, visit www.ocean.software.

About the Belgian Air Component

The Belgian Air Component celebrated last year its 70th anniversary, but its roots can be traced back to 1907. Today, the Belgian Air Component, is considered as one of the most active Air Forces in the world with a pivotal role in NATO. The Belgian Air Component is a small but reliable partner for its allies, active in homeland and abroad. Besides its national duties like QRA and SAR, the Belgian Air Component participates in a broad range of operations. Outstanding technology and equipment is mandatory to achieve this.

MEDIA CONTACT

For high-res imagery, please contact:

Nick Timms

Burson-Marsteller for Ocean Software

nick.timms@bm.com

+61-2-9928-1519

Sacha Blomer

Ocean Software

Sachab@ocean.com.au

+61-3-8614-7200

]]>
PRN: 10 Year Haemophagocytic lymphohistiocytosis (HLH) Forecasts in 14 Major Markets 2016-2026 - Research and Markets Thu, 23 Feb 2017 22:30:43 +0100 http://comunicati.net/comunicati/turismo/varie/422737.html http://comunicati.net/comunicati/turismo/varie/422737.html PR Newswire Turismo PR Newswire Turismo

10 Year Haemophagocytic lymphohistiocytosis (HLH) Forecasts in 14 Major Markets 2016-2026 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Haemophagocytic lymphohistiocytosis (HLH) Forecast in 14 Major Markets 2016-2026" report to their offering.

Haemophagocytic lymphohistiocytosis (HLH) is an extremely rare haematological disorder. It occurs when there is an uncontrollable proliferation of hyper-activated macrophages and T-lymphocytes. The hyper-activated macrophages engulf haematopoietic cells resulting in a deregulated immune system, which in turn attacks various tissues in the body. The weakened body becomes susceptible to infection.

This report provides the current incident population for Haemophagocytic lymphohistiocytosis across 14 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Denmark, Norway, Sweden, Finland, Netherlands, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of HLH have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HLH include:

- Autoimmune conditions
- Leukaemia
- Lymphomas
- HSCT
- Infection (especially with EBV)
- Diabetes
- Obesity
- COPD
- Heart Failure

Reasons to Buy

- Able to quantify patient populations in global Haemopha! gocytic lymphohistiocytosis market to target the development o! f future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of Haemophagocytic lymphohistiocytosis and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Haemophagocytic lymphohistiocytosis's incident population.
- Identify sub-populations within Haemophagocytic lymphohistiocytosis which require treatment.
- Gain an understanding of the specific markets that have the largest number of Haemophagocytic lymphohistiocytosis disease patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognos! is & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for HLH

10. Features of HLH patients
10.1 Classification of HLH
10.2 Aetiology of Secondary HLH

11. Symptoms of HLH
11.1 Symptoms of Primary HLH
11.2 Symptoms of Secondary HLH

12. Abbreviations used in the report

13. Patient-Based Offering

14. Online Pricing Data and Platforms

15. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/hrbwdp/haemophagocytic

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Fibromyalgia Drugs Price Analysis and Strategies 2016-2021: Price Data for Market Sizing, Drug Sales Forecast, Budgeting, Competitive Intelligence, HEOR, and Reimbursement - Research and Markets Thu, 23 Feb 2017 22:00:22 +0100 http://comunicati.net/comunicati/turismo/varie/422736.html http://comunicati.net/comunicati/turismo/varie/422736.html PR Newswire Turismo PR Newswire Turismo

Fibromyalgia Drugs Price Analysis and Strategies 2016-2021: Price Data for Market Sizing, Drug Sales Forecast, Budgeting, Competitive Intelligence, HEOR, and Reimbursement - Research and Markets

  [23-February-2017]  

DUBLIN, Feb. 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Fibromyalgia Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Fibromyalgia Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Fibromyalgia market.

The research answers the following questions:

  • What are the key drugs marketed for Fibromyalgia and their clinical attributes? How are they positioned in the Global Fibromyalgia market?
  • What are the unit prices and annual treatment cost for Fibromyalgia therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Fibromyalgia drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Fibromyalgia?

Research Scope:

  • Fibromyalgia Treatment Options - Identify key drugs marketed and prescribed for Fibromyalgia in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Fibromyalgia Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Fibromyalgia
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Fibromyalgia market
  • Fibromyalgia Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Fibromyalgia in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Fibromyalgia New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Fibromyalgia are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Fibromyalgia drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Fibromyalgia market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/lpw5tz/fibromyalgia

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

]]>
PRN: Global Depression Drugs Price Analysis and Strategies 2016-2021: Drugs Price Data for Market Sizing, Drug Sales Forecast, Budgeting, Competitive Intelligence, HEOR, and Reimbursement - Research and Markets Thu, 23 Feb 2017 21:30:09 +0100 http://comunicati.net/comunicati/turismo/varie/422734.html http://comunicati.net/comunicati/turismo/varie/422734.html PR Newswire Turismo PR Newswire Turismo

Global Depression Drugs Price Analysis and Strategies 2016-2021: Drugs Price Data for Market Sizing, Drug Sales Forecast, Budgeting, Competitive Intelligence, HEOR, and Reimbursement - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Depression Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Depression Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Depression market.

The research answers the following questions:

  • What are the key drugs marketed for Depression and their clinical attributes? How are they positioned in the Global Depression market?
  • What are the unit prices and annual treatment cost for Depression therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Depression drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Depression?

Research Scope:

  • Depression Treatment Options - Identify key drugs marketed and prescribed for Depression in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Depression Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Depression
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Depression market
  • Depression Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Depression in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Depression New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Depression are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Depression drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Depression market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/hxh6wx/depression_drugs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Type 1 Diabetes Drugs Price Analysis and Strategies 2016-2021 - Research and Markets Thu, 23 Feb 2017 21:15:16 +0100 http://comunicati.net/comunicati/turismo/varie/422733.html http://comunicati.net/comunicati/turismo/varie/422733.html PR Newswire Turismo PR Newswire Turismo

Type 1 Diabetes Drugs Price Analysis and Strategies 2016-2021 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Type 1 Diabetes Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Type 1 Diabetes Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Type 1 Diabetes market.

The research answers the following questions:

  • What are the key drugs marketed for Type 1 Diabetes and their clinical attributes? How are they positioned in the Global Type 1 Diabetes market?
  • What are the unit prices and annual treatment cost for Type 1 Diabetes therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Type 1 Diabetes drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Type 1 Diabetes?

Research Scope:

  • Type 1 Diabetes Treatment Options - Identify key drugs marketed and prescribed for Type 1 Diabetes in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Type 1 Diabetes Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Type 1 Diabetes
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Type 1 Diabetes market
  • Type 1 Diabetes Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Type 1 Diabetes in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Type 1 Diabetes New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Type 1 Diabetes are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Type 1 Diabetes drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Type 1 Diabetes market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/dj33nx/type_1_diabetes

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: DoubleVerify Partners with AOL to Drive Greater Trust & Accountability for Advertisers Thu, 23 Feb 2017 21:00:28 +0100 http://comunicati.net/comunicati/turismo/varie/422731.html http://comunicati.net/comunicati/turismo/varie/422731.html PR Newswire Turismo PR Newswire Turismo

DoubleVerify Partners with AOL to Drive Greater Trust & Accountability for Advertisers

  [23-February-2017]  

Global Pre-Bid Data Integration Enables Brands to Deliver Highest Ad Quality with Programmatic Buying

NEW YORK, Feb. 23, 2017 /PRNewswire/ -- DoubleVerify (DV), the recognized leader in digital quality solutions, today announced an expanded relationship with AOL that integrates DV ad quality data into the ONE by AOL advertiser and publisher platforms. Brand advertisers will now have access to the complete suite of DV data solutions to authenticate the quality of their digital ads for brand safety, fraud, and viewability when making real-time bid decisions on the ONE by AOL platform.

Advertisers can now use DV ad quality data to target the highest quality Authentic Impressions for their video and display media buys across ONE by AOL.  The combination of DV proprietary targeting data together with AOL's access to quality digital inventory will further improve the performance and results of programmatic buying for brand advertisers and their agencies.

"Integrating the DoubleVerify pre-bid segments is a natural step for AOL," said Tim Mahlman, President, Platforms at AOL. "We aim to be an agnostic platform that offers the best-in-breed technology partners for our clients to leverage as they build brands people love.  DoubleVerify is a leader in the marketplace and we are thrilled to work with them further to drive trust and accountability."

"We are proud to expand our relationship with AOL and to integrate our pre-bid ad quality data into ONE by AOL," said Wayne Gattinella, President and CEO at DoubleVerify. "DoubleVerify has the most robust pre-bid targeting solution in the marketplace and now this rich data is available to our many clients who leverage ONE by AOL as their programmatic platform."

The integration of DV pre-bid targeting data with ONE by AOL is now available to all DV and AOL customers.

For more information about DV and their complete suite of solutions, please visit: http://www.doubleverify.com.

About DoubleVerify
DoubleVerify (DV), is the marketing technology and services company that authenticates the quality and performance of marketing investments across digital and social platforms. For brands and publishers alike, the DV Authentic Impression® delivers a precise and holistic view of value across media placements, consumer engagement and consumer profiles. Since 2008, DV has been focused on building a better industry and driving results for hundreds of Fortune 500 companies. Learn more at doubleverify.com.

]]>
PRN: Cervical Cancer Drugs Price Analysis and Strategies 2016-2021 - Research and Markets Thu, 23 Feb 2017 21:00:28 +0100 http://comunicati.net/comunicati/turismo/varie/422732.html http://comunicati.net/comunicati/turismo/varie/422732.html PR Newswire Turismo PR Newswire Turismo

Cervical Cancer Drugs Price Analysis and Strategies 2016-2021 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cervical Cancer Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Cervical Cancer Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Cervical Cancer market.

The research answers the following questions:

  • What are the key drugs marketed for Cervical Cancer and their clinical attributes? How are they positioned in the Global Cervical Cancer market?
  • What are the unit prices and annual treatment cost for Cervical Cancer therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Cervical Cancer drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Cervical Cancer?

Research Scope:

  • Cervical Cancer Treatment Options - Identify key drugs marketed and prescribed for Cervical Cancer in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Cervical Cancer Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Cervical Cancer
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Cervical Cancer market
  • Cervical Cancer Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Cervical Cancer in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Cervical Cancer New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Cervical Cancer are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Cervical Cancer drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Cervical Cancer market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/h9sdgc/cervical_cancer

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Brain Cancer Drugs Price Analysis and Strategies 2016-2021 - Research and Markets Thu, 23 Feb 2017 21:00:26 +0100 http://comunicati.net/comunicati/turismo/varie/422730.html http://comunicati.net/comunicati/turismo/varie/422730.html PR Newswire Turismo PR Newswire Turismo

Brain Cancer Drugs Price Analysis and Strategies 2016-2021 - Research and Markets

  [23-February-2017]  


DUBLIN, Feb 23, 2017 /PRNewswire/ --


Research and Markets has announced the addition of the "Brain Cancer Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Brain Cancer Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Brain Cancer market.

The research answers the following questions:

  • What are the key drugs marketed for Brain Cancer and their clinical attributes? How are they positioned in the Global Brain Cancer market?
  • What are the unit prices and annual treatment cost for Brain Cancer therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Brain Cancer drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Brain Cancer?

Research Scope:

  • Brain Cancer Treatment Options - Identify key drugs marketed and prescribed for Brain Cancer in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Brain Cancer Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Brain Cancer
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Brain Cancer market
  • Brain Cancer Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Brain Cancer in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Brain Cancer New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Brain Cancer are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Brain Cancer drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Brain Cancer market
  • Identify the effective pricing for a new drug


Key Topics Covered:

1. Brain Cancer Treatment Options
2. Brain Cancer Drugs Clinical Attributes
3. Brain Cancer Drugs Market Positioning
4. Brain Cancer Drugs Price Analysis
4.1. Brain Cancer Drugs Price Analysis - US
4.2. Brain Cancer Drugs Price Analysis - Germany
4.3. Brain Cancer Drugs Price Analysis - France
4.4. Brain Cancer Drugs Price Analysis - Italy
4.5. Brain Cancer Drugs Price Analysis - Spain
4.6. Brain Cancer Drugs Price Analysis - UK
4.7. Brain Cancer Drugs Price Analysis - Japan
5. Brain Cancer Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
6.1. Drug Pricing & Reimbursement Landscape - US
6.2. Drug Pricing & Reimbursement Landscape - Germany !
6.3. Drug Pricing & Reimbursement Landscape - France
6.4. Drug Pricing & Reimbursement Landscape - Italy
6.5. Drug Pricing & Reimbursement Landscape - Spain
6.6. Drug Pricing & Reimbursement Landscape - UK
6.7. Drug Pricing & Reimbursement Landscape - Japan
7. Brain Cancer Drugs Price Forecast
8. Brain Cancer Market Unmet Needs
9. Brain Cancer New Drug Pricing
10. Research Methodology

Table 1: Brain Cancer Marketed Drugs, Global, 2016
Table 2: Brain Cancer Drugs Clinical Attribute Analysis, Global, 2016
Table 3: Brain Cancer Drugs Unit Price, Global, 2012 - 2016
Table 4: Brain Cancer Drugs Annual Treatment Cost, Global, 2012 - 2016
Table 5: Brain Cancer Drugs Unit Price, US, 2012 - 2016
Table 6: Brain Cancer Drugs Annual Treatment Cost, US, 2012 ! - 2016
Table 7: Brain Cancer Drugs Unit Price, Germany, 2012 - 2016
Table 8: Brain Cancer Drugs Annual Treatment Cost, Germany, 2012 - 2016
Table 9: Brain Cancer Drugs Unit Price, France, 2012 - 2016
Table 10: Brain Cancer Drugs Annual Treatment Cost, France, 2012 - 2016
Table 11: Brain Cancer Drugs Unit Price, Italy, 2012 - 2016
Table 12: Brain Cancer Drugs Annual Treatment Cost, Italy, 2012 - 2016
Table 13: Brain Cancer Drugs Unit Price, Spain, 2012 - 2016
Table 14: Brain Cancer Drugs Annual Treatment Cost, Spain, 2012 - 2016
Table 15: Brain Cancer Drugs Unit Price, UK, 2012 - 2016
Table 16: Brain Cancer Drugs Annual Treatment Cost, UK, 2012 - 2016
Table 17: Brain Cancer Drugs Unit Price, Japan, ! 2012 - 2016
Table 18: Brain Cancer Drugs Annual Treatment Cost, Japan, 2012 - 2016
Table 19: Brain Cancer Drugs Price Comparison Benchmarks, Global, 2016
Table 20. Drug Pricing Landscape by Countries, 2016
Table 21: Drug Reimbursement Landscape by Countries, 2016
Table 22: Brain Cancer Drugs Price Forecast, Global, 2016 - 2021
Table 23: Brain Cancer Drugs Price Forecast, US, 2016 - 2021
Table 24: Brain Cancer Drugs Price Forecast, Germany, 2016 - 2021
Table 25: Brain Cancer Drugs Price Forecast, France, 2016 - 2021
Table 26: Brain Cancer Drugs Price Forecast, Italy, 2016 - 2021
Table 27: Brain Cancer Drugs Price Forecast, Spain, 2016 - 2021
Table 28: Brain Cancer Drugs Price Forecast, UK, 2016 - 2021
Table 29: Brain Cancer Drugs Price Forecast, Japan, 2016 - 2021
Table 30: Bra! in Cance r Market Unmet Needs
Table 31: Brain Cancer New Drugs Pricing, Global, 2016 - 2021

Figure 1: Brain Cancer Drugs Market Positioning, Global, 2016
Figure 2: Brain Cancer Drugs Unit Price, Global, 2012 - 2016
Figure 3: Brain Cancer Drugs Annual Treatment Cost, Global, 2012 - 2016
Figure 4: Brain Cancer Drugs Unit Price, US, 2012 - 2016
Figure 5: Brain Cancer Drugs Annual Treatment Cost, US, 2012 - 2016
Figure 6: Brain Cancer Drugs Unit Price, Germany, 2012 - 2016
Figure 7: Brain Cancer Drugs Annual Treatment Cost, Germany, 2012 - 2016
Figure 8: Brain Cancer Drugs Unit Price, France, 2012 - 2016
Figure 9: Brain Cancer Drugs Annual Treatment Cost, France, 2012 - 2016
Figure 10: Brain Cancer Drugs Unit Price, Italy, 2012 - 2016
Figure 11: Brain Cancer Dru! gs Annual Treatment Cost, Italy, 2012 - 2016
Figure 12: Brain Cancer Drugs Unit Price, Spain, 2012 - 2016
Figure 13: Brain Cancer Drugs Annual Treatment Cost, Spain, 2012 - 2016
Figure 14: Brain Cancer Drugs Unit Price, UK, 2012 - 2016
Figure 15: Brain Cancer Drugs Annual Treatment Cost, UK, 2012 - 2016
Figure 16: Brain Cancer Drugs Unit Price, Japan, 2012 - 2016
Figure 17: Brain Cancer Drugs Annual Treatment Cost, Japan, 2012 - 2016
Figure 18: Brain Cancer Drugs Price Comparison Benchmarks, Global, 2016
Figure 19: Brain Cancer Drugs Price Forecast, Global, 2016 - 2021
Figure 20: Brain Cancer Drugs Price Forecast, US, 2016 - 2021
Figure 21: Brain Cancer Drugs Price Forecast, Germany, 2016 - 2021
Figure 22: Brain Cancer Drugs ! Price Forecast, France, 2016 ! - 2021 < br/>Figure 23: Brain Cancer Drugs Price Forecast, Italy, 2016 - 2021
Figure 24: Brain Cancer Drugs Price Forecast, Spain, 2016 - 2021
Figure 25: Brain Cancer Drugs Price Forecast, UK, 2016 - 2021
Figure 26: Brain Cancer Drugs Price Forecast, Japan, 2016 - 2021
Figure 27: Brain Cancer New Drugs Pricing, Global, 2016 - 2021

For more information about this report visit http://www.researchandmarkets.com/research/kkx8wk/brain_cancer

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



]]>
PRN: Liver Fibrosis Drugs Price Analysis and Strategies 2016-2021: Identify the Effective Pricing for a New Drug - Research and Markets Thu, 23 Feb 2017 20:45:17 +0100 http://comunicati.net/comunicati/turismo/varie/422729.html http://comunicati.net/comunicati/turismo/varie/422729.html PR Newswire Turismo PR Newswire Turismo

Liver Fibrosis Drugs Price Analysis and Strategies 2016-2021: Identify the Effective Pricing for a New Drug - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Liver Fibrosis Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Liver Fibrosis Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Liver Fibrosis market.

The research answers the following questions:

  • What are the key drugs marketed for Liver Fibrosis and their clinical attributes? How are they positioned in the Global Liver Fibrosis market?
  • What are the unit prices and annual treatment cost for Liver Fibrosis therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Liver Fibrosis drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Liver Fibrosis?

Research Scope:

  • Liver Fibrosis Treatment Options - Identify key drugs marketed and prescribed for Liver Fibrosis in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Liver Fibrosis Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Liver Fibrosis
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Liver Fibrosis market
  • Liver Fibrosis Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Liver Fibrosis in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Liver Fibrosis New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Liver Fibrosis are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Liver Fibrosis drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Liver Fibrosis market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/qlnbsv/liver_fibrosis

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Oesophageal Cancer Drugs Price Analysis and Strategies 2016-2021 - Research and Markets Thu, 23 Feb 2017 20:34:24 +0100 http://comunicati.net/comunicati/turismo/varie/422727.html http://comunicati.net/comunicati/turismo/varie/422727.html PR Newswire Turismo PR Newswire Turismo

Oesophageal Cancer Drugs Price Analysis and Strategies 2016-2021 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Oesophageal Cancer Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Oesophageal Cancer Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Oesophageal Cancer market.

The research answers the following questions:

  • What are the key drugs marketed for Oesophageal Cancer and their clinical attributes? How are they positioned in the Global Oesophageal Cancer market?
  • What are the unit prices and annual treatment cost for Oesophageal Cancer therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Oesophageal Cancer drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Oesophageal Cancer?

Research Scope:

  • Oesophageal Cancer Treatment Options - Identify key drugs marketed and prescribed for Oesophageal Cancer in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Oesophageal Cancer Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Oesophageal Cancer
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Oesophageal Cancer market
  • Oesophageal Cancer Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Oesophageal Cancer in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Oesophageal Cancer New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Oesophageal Cancer are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Oesophageal Cancer drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Oesophageal Cancer market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/694246/oesophageal

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Menopause Drugs Price Analysis and Strategies 2016-2021 - Research and Markets Thu, 23 Feb 2017 20:15:18 +0100 http://comunicati.net/comunicati/turismo/varie/422726.html http://comunicati.net/comunicati/turismo/varie/422726.html PR Newswire Turismo PR Newswire Turismo

Menopause Drugs Price Analysis and Strategies 2016-2021 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Menopause Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Menopause market.

The research answers the following questions:

  • What are the key drugs marketed for Menopause and their clinical attributes? How are they positioned in the Global Menopause market?
  • What are the unit prices and annual treatment cost for Menopause therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Menopause drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Menopause?

Research Scope:

  • Menopause Treatment Options - Identify key drugs marketed and prescribed for Menopause in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Menopause Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Menopause
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Menopause market
  • Menopause Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Menopause in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Menopause New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Menopause are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Menopause drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Menopause market
  • Identify the effective pricing for a new drug

Key Topics Covered:

1. Menopause Treatment Options

2. Menopause Drugs Clinical Attributes

3. Menopause Drugs Market Positioning

4. Menopause Drugs Price Analysis

5. Menopause Drugs Price Benchmarks

6. Drug Pricing & Reimbursement Landscape

7. Menopause Drugs Price Forecast

8. Menopause Market Unmet Needs

9. Menopause New Drug Pricing

For more information about this report visit http://www.researchandmarkets.com/research/fhdxld/menopause_drugs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Global Autism Spectrum Disorder Drugs Price Analysis and Strategies 2016-2021 - Research and Markets Thu, 23 Feb 2017 20:00:19 +0100 http://comunicati.net/comunicati/turismo/varie/422725.html http://comunicati.net/comunicati/turismo/varie/422725.html PR Newswire Turismo PR Newswire Turismo

Global Autism Spectrum Disorder Drugs Price Analysis and Strategies 2016-2021 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Autism Spectrum Disorder Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Autism Spectrum Disorder Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Autism Spectrum Disorder market.

The research answers the following questions:

  • What are the key drugs marketed for Autism Spectrum Disorder and their clinical attributes? How are they positioned in the Global Autism Spectrum Disorder market?
  • What are the unit prices and annual treatment cost for Autism Spectrum Disorder therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Autism Spectrum Disorder drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Autism Spectrum Disorder?

Research Scope:

  • Autism Spectrum Disorder Treatment Options - Identify key drugs marketed and prescribed for Autism Spectrum Disorder in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Autism Spectrum Disorder Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Autism Spectrum Disorder
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Autism Spectrum Disorder market
  • Autism Spectrum Disorder Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Autism Spectrum Disorder in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Autism Spectrum Disorder New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Autism Spectrum Disorder are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Autism Spectrum Disorder drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Autism Spectrum Disorder market
  • Identify the effective pricing for a new drug

Key Topics Covered:

1. Autism Spectrum Disorder Treatment Options

2. Autism Spectrum Disorder Drugs Clinical Attributes

3. Autism Spectrum Disorder Drugs Market Positioning

4. Autism Spectrum Disorder Drugs Price Analysis

5. Autism Spectrum Disorder Drugs Price Benchmarks

6. Drug Pricing & Reimbursement Landscape

7. Autism Spectrum Disorder Drugs Price Forecast

8. Autism Spectrum Disorder Market Unmet Needs

9. Autism Spectrum Disorder New Drug Pricing

For more information about this report visit http://www.researchandmarkets.com/research/2vvrzb/autism_spectrum

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: France Proton Therapy Market - Expected to Be More Than USD 1.5 Billion by the Year 2021 - Research and Markets Thu, 23 Feb 2017 19:45:15 +0100 http://comunicati.net/comunicati/turismo/varie/422723.html http://comunicati.net/comunicati/turismo/varie/422723.html PR Newswire Turismo PR Newswire Turismo

France Proton Therapy Market - Expected to Be More Than USD 1.5 Billion by the Year 2021 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb. 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "France Proton Therapy Market, Forecast, Reimbursement Policies & Patients Treated at Centers" report to their offering.

France Proton Therapy Market is expected to be more than USD 1.5 Billion by the year 2021. France Proton Therapy actual market is expected to almost double in future from its current market size in 2016. So considering the need from patient perspective France had modified all two Proton Therapy Centers with latest technological up-gradation to enhance the capacity to treat more patients.

Diversified range of advanced radiation therapy techniques and technologies are available, such as Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT) and others. But proton is better one, due to the physical properties of protons, which stop at a given depth and deliver the largest part of their energy the beams deliver equal or higher radiation to the target while conveying fewer doses to surrounding healthy tissues.

This report studies the market in two ways a) Actual Market b) Untapped Market. The report also talks about list of all operational and future Proton Therapy centers; Economics of proton therapy including Reimbursement Policies. The report also studies the Proton Therapy Revenue 3 Companies.

Key Questions Answered in the Report:

  • What is the Proton Therapy Market in France & its growth potential in Future?
  • What is the untapped market in France Proton Therapy and its Future?
  • How many Proton Therapy Centers are operating in France?
  • What is the number of people being treated in these Proton Therapy Centers yearly?
  • Is Proton Therapy Treatment being covered in the Reimbursements policies of France?
  • What are the sales of Proton Therapy Companies Globally (IBA, Varian, Elekta)?

Key Topics Covered:

1. Executive Summary

2. Germany Proton Therapy Market - Actual & Potential Market

3. Germany Proton Therapy Patient Number - Actual and Potential

4. Germany - List of Proton Therapy Centers

5. Germany - Proton Therapy Treated Patients by Centers

6. Proton Therapy - Reimbursement Policies

7. Components of a Standard Proton Therapy Center

8. Global Proton Therapy - Company Analysis (2010 - 2021)

9. Proton Therapy - Driving Factors

10. Proton Therapy - Challenges

Companies Mentioned

  • Elekta
  • IBA
  • Varian Medical Systems

For more information about this report visit http://www.researchandmarkets.com/research/ccqjmf/france_proton

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

]]>
PRN: Complete Teardown Analysis of Enphase Energy's Enphase S280 VA Solar Microinverter with Comparison with Enphase's Previous Microinverters - Research and Markets Thu, 23 Feb 2017 19:45:15 +0100 http://comunicati.net/comunicati/turismo/varie/422724.html http://comunicati.net/comunicati/turismo/varie/422724.html PR Newswire Turismo PR Newswire Turismo

Complete Teardown Analysis of Enphase Energy's Enphase S280 VA Solar Microinverter with Comparison with Enphase's Previous Microinverters - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Enphase S280 VA Solar Microinverter: Technology Analysis" report to their offering.

In a continuously expanding market, with a forecast compound annual growth rate of 5.9% through to 2021, Enphase Energy remains the world's leading solar microinverter company.  It has shipped more than 11 million units to date, with 460,000 residential and commercial photovoltaic installations worldwide.

Designed for high-powered, 60-cell modules, the advanced grid-ready Enphase S280 Microinverter achieves the highest efficiency for module-level power electronics and reduces the cost per watt. With its all-AC approach, the S280 simplifies design and installation for 280VA installations, and delivers optimal energy harvest. The S280 is compatible with storage systems, including battery management systems.

This inverter is the result of Enphase's desire to enhance integration with a new generation of dedicated application specific integrated circuit (ASIC) in its topology. This approach reduces the size and number of components and improves reliability! , safety and functionality.

Based on a complete teardown analysis of the Enphase S280, this report provides the system's complete bill of materials (BOM) and manufacturing cost. Physical and cost analysis of the microinverter ASIC is also included in the report.

A comparison with Enphase's previous microinverters is provided, highlighting the improvement made at the hardware level resulting in a shorter bill of material and significant cost reduction.

Key Topics Covered:

Overview / Introduction

- Executive Summary
- Reverse Costing Methodology

Company Profile

- Enphase
- S280 features

Physical Analysis

- Views and Dimensions of the Inverter
- Inverter Opening
- Cable Support
- Connectors of the Inverter
- Electronic Board       

- Top Side - Overview
- Top Side - High definition photo
- Top Side - P.C.B. Markings
- Top ! Side - Main Component Markings
- Top Side - Main Componen! t Identi fication
- Top Side - Discrete Component Markings
- Top Side - Discrete Component Identification
- Top Side - Magnetic Component Identification
- Top Side - Protection Component Identification
- Bottom Side - High Definition Photo
- Bottom Side - Component Identification
- Potting Compound Analysis

Cost Analysis             

- Investigating the BOM
- Estimation of the Cost of the PCB
- Estimation of the Cost of the Enphase MB8AC3100 ASIC
- BOM Cost - Electronic Board
- Estimation of the Cost of the Housing Parts
- BOM Housing
- Material Cost Breakdown
- Investigating the Added Value (AV) Cost
- Electronic Board Manufacturing Flow
- Details of the Electronic Board AV Cost
- Details of the System Assembly AV Cost
- Added Value Cost Breakdown
- Manufacturing Cost Breakdown

For more information about this report visit http://www.researchandmarkets.com/research/bp9zhr/enphase_s280_va

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Physicist Who Helped Power Villages in India Named Editor of New Cell Press Energy Journal Thu, 23 Feb 2017 19:28:18 +0100 http://comunicati.net/comunicati/turismo/varie/422721.html http://comunicati.net/comunicati/turismo/varie/422721.html PR Newswire Turismo PR Newswire Turismo

Physicist Who Helped Power Villages in India Named Editor of New Cell Press Energy Journal

  [23-February-2017]  

CAMBRIDGE, Massachusetts, February 23, 2017 /PRNewswire/ --

Philip Earis, a former editor at the Royal Society of Chemistry and the founder of a non-profit that develops and installs solar energy technology in off-grid communities in Western India, has been named the inaugural editor of Joule, a new journal spanning energy research across scales and disciplines. Joule (@Joule_CP), launching fall 2017, will be the second physical sciences journal, after Chem, published by Cell Press, home of the high-impact life sciences journal Cell. Articles can now be submitted at www.cell.com/joule/home.

     (Photo: http://mma.prnewswire.com/media/471540/Philip_Earis.jpg )
     (Photo: http://mma.prnewswire.com/media/471541/Cover_of_Joule.jpg )

"The need for more sustainable energy is one of the key challenges facing the world today and there's an increasing realization that no one group of people, nor one discipline, can address that challenge alone," Earis says. "Energy researchers with different backgrounds at different scales need to come together: Joule will be a home for cross-pollination of important results in energy research and a community-spanning forum where ideas are amplified."

Earis, who studied physics at Cambridge University, started his career in publishing at the Royal Society of Chemistry. He served as the executive editor of a portfolio of physical science journals, including Energy & Environmental Science, which he launched, Nanoscale, Green Chemistry, and Catalysis Science & Technology. In this role, Earis traveled the world talking with researchers and helped build a greater presence for the society in Asia, increasing submissions and readership. He then took an opportunity to move from Great Britain to India in 2013 to build partnerships between the society and the Indian scientific community.

While in India, Earis was struck by the energy problems that many people around him were facing. In response, he founded a social enterprise non-profit, dubbed Project Light, in collaboration with Indian scientists and research institutes. Together, they developed solar energy solutions for marginalized off-grid communities around Mumbai and Maharashtra state and worked with those communities to install new devices and monitor their performance.

"For people not even on the first rung of the energy ladder, disadvantage is entrenched: adults can't really work or children study after dark, and primitive energy solutions such as burning kerosene are polluting, dangerous, and expensive," Earis says. "I felt with my science background and my connections, I could bring together researchers to address some of those problems."

Two years after electrifying villages in West India with solar panels, Earis returned to the UK and accepted his new role at Joule. He will connect chemists, engineers, physicists, materials scientists, policy makers, and others in the energy community to build the journal's first issue, which will showcase insightful, impactful, and forward-looking energy research.

"We're excited to grow our physical sciences offerings with Philip on the team," says Cell Press CEO Emilie Marcus. "His experience in the laboratory, as an editor, and working with communities to solve energy problems makes him a natural fit to bring together researchers looking at sustainability from so many different fields. We have high expectations for Joule to make a real difference in addressing the world's energy challenges."

---

About Cell Press 

Cell Press (@CellPressNews), an imprint of Elsevier, is a leading publisher of scientific research and reviews. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research. www.cell.com

About Elsevier 

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic ref! erence works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contact
Joseph Caputo
Press Office, Cell Press
+1-617-397-2802
jcaputo@cell.com
press@cell.com

]]>
PRN: Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022: Focus on Melanoma, Leukemia Brain Tumor & Lung, Breast, Colorectal, Prostate, Cervical, Gastric & Renal Cancers - Research and Markets Thu, 23 Feb 2017 19:15:12 +0100 http://comunicati.net/comunicati/turismo/varie/422719.html http://comunicati.net/comunicati/turismo/varie/422719.html PR Newswire Turismo PR Newswire Turismo

Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022: Focus on Melanoma, Leukemia Brain Tumor & Lung, Breast, Colorectal, Prostate, Cervical, Gastric & Renal Cancers - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022" report to their offering.

The report Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022 is an inclusive report which covers the current and future opportunities for the personalized cancer vaccines and its varied inclinations in oncology. The report throws a light over the clinical relevance of personalized forms and identifies the risk and commercial aspects along with the potential outcome for the success of personalized cancer vaccines in the upcoming future directions.

Oncological segment has gained a great momentum with the advent of modern technologies and the better equipped sequencing methodology. Over the past years, there has been gradual paradigm shift from traditional medicine and accelerated acceptance towards the precision medication. Physicians are opting for the personalization of the medicines according to the genomic makeup of the patient.

During the last decade, great efforts have been made to develop immunotherapeutic approaches for the treatment of malignant diseases as alternatives to traditional chemotherapy and radiotherapy. A quintessential goal of immunotherapy in cancer is treatment with vaccines that elicit potent anti-tumor immune responses without side effects. The upsurge of immunotherapeutics in oncology is remarkable and the trail towards getting personalized is in future trends. With the development of the pharmacogenomics and genome mapping resolutions towards human genome are making personalized! vaccines to be more efficacious. The platform for the personalization of vaccines had been built by the human genome project.

Geographically, the acceptance of personalization is greater in the western world as both the new and old vaccine approaches towards the cancer are transforming the landscape of the major markets of western world including US, Western Europe and Japan. In contrary the concept is less influential in the low and middle income countries. Nevertheless, in the upcoming time the improvement will surely administer the challenges of cost and distribution which will aid the personalization in the Asia-Pacific regions.

The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxic! ity. In terms of cost and savings the payers found personaliza! tion to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.

In contrary, it also provides better future opportunities for pharmaceuticals too although there are several challenges and unmet needs which has to be defined first. Many pharmaceutical companies have calculated the improvised vision for the right drug, right patient and the right time. This concept saves the resources, time and provides ample opportunities to achieve substantial medications for the investors.

The future potential of personalized cancer vaccines for the detection, management and preventing diseases is primarily dependent on the ongoing genomic projects, merging translational medicines and advances in personal genetic testing and developing targeted therapy. Such innovative therapies are also welcomed by the physicians as these approaches minimize the trial and error diagnosis and treatment. The persona! lized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.

Key Topics Covered:

1. Personalized Vaccine: Trail Towards Cancer
1.1 Prologue to Personalized Cancer Immunotherapy
1.2 Advent of Personalized Cancer Vaccine

2. Perception of Personalized Vaccinomics
2.1 Genetic Heterogeneity by HLA System
2.2 Genesis of Tumor Neoantigens

3. Identification of Tumor Neoantigens
3.1 Conventional Methodologies
3.2 Next Genome Sequencing Approach

4. Development of Personalized Vaccines
4.1 Development Process of Personal Cancer Vaccine 4.2 Economic Aspects of Personalized Cancer Vaccine
5. Me chanism of Personalized Vaccines
5.1 Rationale of Personal Cancer Vaccine
5.2 Neoantigens & Immune Interactions

6. Application of Neoantigens in Therapeutics
6.1 Adoptive T Cell Therapy
6.2 Checkpoint Blockade

7. Categories of Personalized Cancer Vaccines
7.1 Personalized Peptide Vaccination (PPV)
7.2 DNA Cancer Vaccines
7.3 RNA Based Vaccines
7.4 Dendritic Cell Vaccines
7.5 Whole Tumor Cell Vaccines
7.6 Recombinant Virus Vaccines

8. Biomarkers for Personalized Vaccines
8.1 Pharmacogenomic Biomarkers
8.2 Prognostic & Predictive Biomarkers
8.3 Immune Checkpoint Biomarkers

9. Personalized Vaccines for Varied Cancers
9.1 Melanoma
9.2 Lung Cancer
9.3 Breast Cancer
9.4 Colorectal Cancer
9.5 Leukemia
9.6 Prostate cancer
9.7 Cervical Cancer
9.8 Gastric Cancer
9.9 Brain Tumor
9.10 Renal Cancer

10. Pharmacogenomic! s of Personalization
10.1 Pharmacogenomics towards Genomic Polymorphism
10.2 Somatic Mutations in Cancer Pharmacogenomics
10.3 Applications of Pharmacogenomics

11. Personalized Vaccines Market Overview
11.1 Market Trends Towards Therapeutic Personalization
11.2 Mergers & Acquisitions for Personalized Therapy

12. Global Personalized Vaccines Market Dynamics
12.1 Personalization Growth Drivers
12.1.1 Increasing Cancer Incidences
12.1.2 Cancer Heterogenetic Environment
12.1.3 High Level of Specificity
12.1.4 Government Initiatives
12.1.5 Reduced Genome Sequencing Cost & Time
12.1.6 Sustained Level of Innovation
12.2 Personalization Major Challenges

13. Global Personalized Cancer Vaccines Market Future Aspects

14. Competitive Landscape
14.1 Advaxis Inc.
14.2 Avax Technologies
14.3 BioNtech
14.4 Celldex
14.5 Genentech Inc.
14.6 Genocea 14.7 ISA Pharmaceuticals
14.8 Merck & Co.
14.! 9 Modern a
14.10 Neon Therapeutics

For more information about this report visit http://www.researchandmarkets.com/research/t6jcgt/personalized

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Driving Value in the Digital Era: Smart Mobility Disrupts the Traditional Dealer Model Thu, 23 Feb 2017 19:07:56 +0100 http://comunicati.net/comunicati/turismo/varie/422718.html http://comunicati.net/comunicati/turismo/varie/422718.html PR Newswire Turismo PR Newswire Turismo

Driving Value in the Digital Era: Smart Mobility Disrupts the Traditional Dealer Model

  [23-February-2017]  

Automation, Electrification, and Mobility as a Service Trends Will Challenge Future Dealerships

SCOTTSDALE, Arizona, Feb. 23, 2017 /PRNewswire/ -- As consumers demand greater transparency, influence, and efficiency from the auto purchasing process, most also wish to minimize time spent at a dealership. In its new smart mobility report, ABI Research finds recent, rapid gains in vehicle technology will soon infiltrate the mainstream automotive market and disrupt traditional business models and consumer experiences.

ABI Research www.abiresearch.com

"Automotive is one of the few major U.S. industries still ripe for disruption," says Susan Beardslee, Senior Analyst at ABI Research. "The rise of electric vehicles, Over the Air updates, and prognostics are reducing the need for service visits to dealerships, as well as challenging the dealers' margins, time to close sales, and required training. Emerging smart mobility trends, such as autonomy and ride sharing, will create opportunities for new market players to drastically shake up the current landscape in the near future."

While disruptive business models have succeeded in other industries, like online giants Amazon and Netflix, state-by-state franchise laws now complicate matters as they continue to impact innovation in sales of new car brands like Tesla.

In the last three years, evolving used car sales models in the U.S. grew rapidly and received increased attention and funding, accruing more than $2 billion for Beepi (merged into Fair), Carvana (backed by DriveTime), and Vroom. U.S. online new car sales are expected to cross over to at least 10% of yearly sales by as early as late 2019. 

Additional online car sale disruptors include Carlypso, Car Saver (with an upcoming pilot in select Walmart stores), MakeMyDeal (a Cox Automotive company), Roadster, and TRUECar. Well-known market players include AutoNation (America's largest auto retailer), Costco, and Edmunds.

"Emerging digital business models, some that have yet to be designed or deployed, will disrupt the entire auto industry," concludes Beardslee. "Profits, personnel, and control within and outside the traditional automotive industry will permanently change. However, significant data that dealerships already possess could be mined for additional profit pools, as well as the generation of new preferences and experiences, such as virtual showroom experiences." 

These findings are from ABI Research's The Future of Dealerships in the Digital Automotive Era (https://www.abiresearch.com/market-research/product/1026409-the-future-of-dealerships-in-the-digital-a/) report. 

About ABI Research

ABI Research stands at the forefront of technology market research, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company's global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: Mackenzie Gavel

Tel: +1.516.624.2542


pr@abiresearch.com

 

Logo - http://mma.prnewswire.com/media/276887/abi_research_logo.jpg  

]]>
PRN: India Carbon Black Market 2011-2025 - Research and Markets Thu, 23 Feb 2017 19:00:30 +0100 http://comunicati.net/comunicati/turismo/varie/422717.html http://comunicati.net/comunicati/turismo/varie/422717.html PR Newswire Turismo PR Newswire Turismo

India Carbon Black Market 2011-2025 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "India Carbon Black Market Study, 2011-2025" report to their offering.

According to India Carbon Black Market Study, 2011-2025, report studies the market size and share of various segments and sub-segments of carbon black market in India during 2011-2025.

The market dynamics section of the report elaborates the factors that are driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment. In addition, report also provides customers analysis including current suppliers, procurement prices & quantity being purchased annually.

All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive carbon black market in India.

India Carbon Black Market Study, 2011-2025 report elaborates the following aspects of carbon black market in India:

- India Carbon Black Market Size! , Share & Forecast
- Segmental Analysis - By Application (Tire, Industrial Rubber, Belts & Hoses, Printing Ink, Moulding Plastics & Others), By Region
- Market Attractiveness Index Analysis
- Competitive Landscape
- Leading Customer Analysis

Key Topics Covered:

1. Product Definition

2. Research Methodology

3. Executive Summary

4. India Carbon Black Production Outlook

5. India Carbon Black Market Outlook

6. India Carbon Black Market Attractiveness Index

7. Pricing Analysis

8. Import-Export Dynamics

9. Competitive Analysis

10. Customer Analysis

11. Customer Analysis (30 Companies)

For more information about this report visit http://www.researchandmarkets.com/research/qqlttn/india_carbon

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>
PRN: Global Anticoagulants (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) Market Outlook 2017-2020 - Research and Markets Thu, 23 Feb 2017 18:45:30 +0100 http://comunicati.net/comunicati/turismo/varie/422716.html http://comunicati.net/comunicati/turismo/varie/422716.html PR Newswire Turismo PR Newswire Turismo

Global Anticoagulants (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) Market Outlook 2017-2020 - Research and Markets

  [23-February-2017]  

DUBLIN, Feb 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market" report to their offering.

This publication on "Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market" provides a comprehensive analysis of the anticoagulants market.

The report includes the cumulative revenue generated by the market players from the sales of anticoagulants, including both generic and patented drugs at manufacturer's price and market share contributed by the sales of heparin, NOACs, Vitamin K Antagonists, and Injectable Direct Inhibitors in the total anticoagulants market.

Further, the market in the study is differentiated on the basis of route of administration into oral and injectable. The market is also segmented by four geographical regions across the globe - North America, Europe, Asia Pacific, and Rest of the World. Detailed snapshot on key regions of the Market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail.

The study also highlights the detailed information about major drug manufacturers in the global anticoagulants market and their respective shares by revenue in 2015. Analysis on patented drugs available in the market, and their approval procedure, timeline, and expected expiries is provided in report to assist new entrants in understanding the mar! ket before investing in the market.

Various marketing analysis factors such as trends and developments and Porter's five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global anticoagulants market has also been discussed along with recommendations from analyst view.

Key Topics Covered:

1. Executive Summary

2. Research Methodology

3. Introduction to Anticoagulants
Uses
Side Effects of Anticoagulants

4. Value Chain Analysis of Global Anticoagulants Market

5. Global Anticoagulants Market Size, 2013 - 2015

6. Global Anticoagulants Market Segmentation
6.1. By Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors), 2015
6.1.1. Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin)
6.1.2. NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etex! ilate, and Edoxaban)
Drug Approval Timelines
Patent Expiries
6.2. By Route of Administration (Oral and Injectables)
6.3. By Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World)

7. Snapshot on North America Anticoagulants Market
By Countries (US and Canada)
7.1. US Market Indicators
7.1.1. US Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
7.1.2. Key Anticoagulants in US
7.1.3. Regulatory Landscape
New Drug Approval Procedure
New Drug Timeline
Generic Drug Approval Procedure
Patents
Exclusivity
Anticoagulants Reimbursement Scenario in the US
7.2. Canada Market Indicators
7.2.1. Canada Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
7.2.2. Cos! t of Key Anticoagulants in Canada
7.2.1. Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, and Bristol-Myers Squibb Canada Co) in Canada Anticoagulants Market, 2015
7.2.2. Regulatory Landscape
Generic Drug Approval Procedure
Patents and Exclusivity
Pharmaceutical Pricing and Reimbursement in Canada

8. Snapshot on Europe Anticoagulants Market
8.1. By Countries (Germany, France, Spain, Italy, UK, and Rest of the Europe)
8.2. Europe Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
8.2.1. Cost of Key Anticoagulants in Europe
8.3. Europe Anticoagulants Market by Companies (Bayer Inc., Boehringer Ingelheim, Pfizer, and Others)
8.4. Regulatory Land! scape
8.4.1. New Drug Approval Procedure
8.4.2. Patents
8.4.3. Reimbursement Scenario in Europe

9. Snapshot on Asia Pacific Anticoagulants Market
By Countries (Japan, Australia, China, India, and Rest of the Asia Pacific)
9.1. Japan Market Indicators
9.1.1. Japan Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.1.2. Key Anticoagulants in Japan
9.1.3. Regulatory Landscape
New Drug Approval Procedure
Patents
9.2. Australia Market Indicators
9.2.1. Australia Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.2.2. Cost of Key Anticoagulants in Australia
9.2.3. Reg! ulatory Landscape
New Drug Approval Procedure
Patent! s
R eimbursement Scenario in Australia
9.3. China Market Indicators
9.3.1. China Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.3.2. Cost of Key Anticoagulants in China
9.3.3. Market Share of Major Players (Bayer China, Boehringer Ingelheim, and Others) in China Anticoagulants Market, 2015
9.3.4. Regulatory Landscape
New Drug Approval Procedure
Patents
9.4. India Market Indicators
9.4.1. India Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.4.1. Cost of Key Anticoagulants in India
9.4.2. Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market
9.4.3. Regulatory Landscape
Ne! w Drug Approval Procedure
Patents
Pricing and Reimbursement Scenario in India

10. Porter's Five Forces Analysis for Global Anticoagulants Market

11. Trends and Developments in Global Anticoagulants Market
11.1. Expanding Therapeutic Indication
11.2. High incidence rate of DVT/PE
11.3. Disadvantages of Patented NOACs over Generic VKAs and Heparin Impacting Market Negatively

12. Global Anticoagulants Market Competitive Landscape
12.1. Market Share of Key Players in Global Anticoagulants Market, 2015
12.2. Company Profiles for Key Manufacturers in Anticoagulants Market
12.2.1. Sanofi
12.2.2. Pfizer Inc.
12.2.3. Boehringer Ingelheim
12.2.4. Bayer AG
12.2.5. Bristol-Myers Squibb Company
12.2.6. Daichi Sankyo company, Limited

13. Future of Global Anticoagulants Market
13.1. Future Outlook and Projections, 2016 - 2020

14. Analyst ! Recommendations

15. Macroeconomic Indicators
15! .1. Agin g Population
15.2. Deaths from Cardiovascular Diseases, 2010 - 2020
15.3. Healthcare Spending, 2010 - 2020

For more information about this report visit http://www.researchandmarkets.com/research/5gbms5/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

]]>